Evidence map›Paper›PMID 26768553›Full record

ReviewToxicology and applied pharmacology2016

Enzymatic oxidative biodegradation of nanoparticles: Mechanisms, significance and applications.

Irina I Vlasova, Alexandr A Kapralov, Zachary P Michael, Seth C Burkert, Michael R Shurin, Alexander Star, Anna A Shvedova, Valerian E Kagan

Abstract readReview
In one paragraph

Review in Toxicology and applied pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Review
  2. Article
  3. Nanodiamonds Co-Localize withPharmaceutics · 2026
    Article
  4. Review
  5. Article
  6. Biocompatibility Research of Magnetosomes Synthesized byInternational journal of molecular sciences · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Irina I VlasovaDepartment of Environmental and Occupational Health, Center for Free Radical and Antioxidant Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15219, United States; Research Institute for Physico-Chemical Medicine, Federal Medico-Biological Agency, Moscow 119453, Russia.
Alexandr A KapralovDepartment of Environmental and Occupational Health, Center for Free Radical and Antioxidant Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15219, United States.
Zachary P MichaelDepartment of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, United States.
Seth C BurkertDepartment of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, United States.
Michael R ShurinDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, United States; Department of Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, United States.
Alexander StarDepartment of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, United States.
Anna A ShvedovaPathology and Physiology Research Branch, Health Effects Laboratory Division (HELD), National Institute for Occupational Safety and Health (NIOSH) and Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26505, United States. Electronic address: ats@cdc.gov.
Valerian E KaganDepartment of Environmental and Occupational Health, Center for Free Radical and Antioxidant Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15219, United States; Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, United States; Departments of Pharmacology and Chemical Biology and Radiation Oncology, University of Pittsburgh, Pittsburgh, PA 15260, United States. Electronic address: kagan@pitt.edu.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
Training and EducationU19AI068021 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GREENBERGER, JOEL S · 2005 to 2019
$44.4M
Regulation of Cardiolin Byosynthesis in Epithelial InjuryP01HL114453 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MALLAMPALLI, RAMA K · 2014 to 2023
$21.3M
NITRIC OXIDE AND METALLOTIONEIMP01HL070807 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RYTER, STEFAN W · 2003 to 2007
$8.1M
Mapping Lipid Oxidation in Traumatic Brain Injury by Mass Spectrometric ImagingR01NS076511 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Hülya Bayir, Valerian E Kagan · 2012 to 2026
$6.8M
Red Cell Tranfusion: Modifier of Lung and Systemic Inflammatory ResponsesR01HL086884 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, JANET SOJUNG · 2007 to 2017
$4.0M
Lipids and Myeloid Cell Function in CancerR01CA165065 · NCI · WISTAR INSTITUTE · PI KAGAN, VALERIAN E, MONTANER, LUIS J · 2012 to 2022
$3.8M
Oxidative Lipidomics in Pediatric Traumatic Brain InjuryR01NS061817 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAYIR, HÜLYA · 2008 to 2018
$3.3M
Lung Oxidative Stress/Inflammation By Carbon NanotubesR01OH008282 · OH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAGAN, VALERIAN E · 2005 to 2014
$2.8M
Oxidative Lipidomics in Pediatric Traumatic Brain InjuryR37NS061817 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Hülya Bayir · 2021 to 2026
$2.2M
Investigations and Mitigation of Carbon Nanomaterial ToxicityR01ES019304 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STAR, ALEXANDER · 2010 to 2014
$1.9M
Oxygenated Species of Cardiolipins as Biomarkers of Mitochondrial DysfunctionR01ES020693 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAGAN, VALERIAN E, TYURINA, YULIA Y · 2011 to 2015
$1.7M
NCI NIH HHS CA165065NCI NIH HHS P30 CA047904NCI NIH HHS P30CA047904NCI NIH HHS R01 CA165065NHLBI NIH HHS HL086884NHLBI NIH HHS P01 HL070807NHLBI NIH HHS P01 HL114453NHLBI NIH HHS R01 HL086884NIAID NIH HHS U19 AI068021NIEHS NIH HHS ES020693NIEHS NIH HHS R01 ES019304NIEHS NIH HHS R01ES019304NIEHS NIH HHS R01 ES020693NINDS NIH HHS NS061817NINDS NIH HHS NS076511NINDS NIH HHS R01 NS061817NINDS NIH HHS R01 NS076511NINDS NIH HHS R37 NS061817NIOSH CDC HHS OH008282NIOSH CDC HHS R01 OH008282
6 · The paper itself

Abstract

Biopersistence of carbon nanotubes, graphene oxide (GO) and several other types of carbonaceous nanomaterials is an essential determinant of their health effects. Successful biodegradation is one of the major factors defining the life span and biological responses to nanoparticles. Here, we review the role and contribution of different oxidative enzymes of inflammatory cells - myeloperoxidase, eosinophil peroxidase, lactoperoxidase, hemoglobin, and xanthine oxidase - to the reactions of nanoparticle biodegradation. We further focus on interactions of nanomaterials with hemoproteins dependent on the specific features of their physico-chemical and structural characteristics. Mechanistically, we highlight the significance of immobilized peroxidase reactive intermediates vs diffusible small molecule oxidants (hypochlorous and hypobromous acids) for the overall oxidative biodegradation process in neutrophils and eosinophils. We also accentuate the importance of peroxynitrite-driven pathways realized in macrophages via the engagement of NADPH oxidase- and NO synthase-triggered oxidative mechanisms. We consider possible involvement of oxidative machinery of other professional phagocytes such as microglial cells, myeloid-derived suppressor cells, in the context of biodegradation relevant to targeted drug delivery. We evaluate the importance of genetic factors and their manipulations for the enzymatic biodegradation in vivo. Finally, we emphasize a novel type of biodegradation realized via the activation of the "dormant" peroxidase activity of hemoproteins by the nano-surface. This is exemplified by the binding of GO to cyt c causing the unfolding and 'unmasking' of the peroxidase activity of the latter. We conclude with the strategies leading to safe by design carbonaceous nanoparticles with optimized characteristics for mechanism-based targeted delivery and regulatable life-span of drugs in circulation.

Indexed as

AnimalsHumansNanoparticlesNanotubes, CarbonNeutrophilsOxidation-ReductionOxidative StressPeroxidasesNanotubes, CarbonPeroxidasesCarbon nanotubesFree radicalsGraphene oxideOxidantsPeroxidase activityPhagocytes

Identifiers

PMID26768553
PMCPMC4811710

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.